Zoetis (ZTS) Price Target Raised to $103.00  Paula Ricardo | Aug 17th, 2018
Zoetis (NYSE:ZTS) had its target price lifted by Argus from $90.00 to $103.00 in a research note released on Tuesday, Marketbeat.com reports. They currently have a buy rating on the stock.
Several other equities research analysts have also recently commented on ZTS. Citigroup reiterated a buy rating and issued a $98.00 price target (up from $85.00) on shares of Zoetis in a research report on Thursday, April 19th. Hilliard Lyons cut shares of Zoetis to a neutral rating in a research report on Thursday, April 19th. They noted that the move was a valuation call. Cantor Fitzgerald set a $90.00 price target on shares of Zoetis and gave the stock a buy rating in a research report on Tuesday, April 24th. Craig Hallum reiterated a buy rating and issued a $94.00 price target (up from $87.00) on shares of Zoetis in a research report on Wednesday, April 25th. Finally, BMO Capital Markets reiterated a hold rating and issued a $80.00 price target on shares of Zoetis in a research report on Wednesday, May 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the stock. Zoetis has an average rating of Buy and a consensus price target of $90.53. Get Zoetis alerts:
Shares of Zoetis stock opened at $91.54 on Tuesday. The company has a current ratio of 4.38, a quick ratio of 2.92 and a debt-to-equity ratio of 2.50. Zoetis has a 52 week low of $60.44 and a 52 week high of $93.67. The stock has a market capitalization of $44.18 billion, a price-to-earnings ratio of 38.14, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The firm had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.38 billion. During the same period in the previous year, the business earned $0.53 earnings per share. Zoetis's revenue for the quarter was up 11.5% compared to the same quarter last year. analysts predict that Zoetis will post 3.07 earnings per share for the current year.
In other Zoetis news, CEO Juan Ramon Alaix sold 135,000 shares of the business's stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $91.55, for a total transaction of $12,359,250.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink . Also, insider Roxanne Lagano sold 2,000 shares of the business's stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $84.76, for a total value of $169,520.00. Following the sale, the insider now owns 22,023 shares in the company, valued at approximately $1,866,669.48. The disclosure for this sale can be found here . In the last 90 days, insiders have sold 197,099 shares of company stock worth $17,978,939. Corporate insiders own 0.35% of the company's stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. Gables Capital Management Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at about $109,000. Sun Life Financial INC increased its holdings in shares of Zoetis by 604.3% in the 2nd quarter. Sun Life Financial INC now owns 1,310 shares of the company's stock valued at $112,000 after purchasing an additional 1,124 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Zoetis by 3,033.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company's stock valued at $120,000 after purchasing an additional 1,365 shares during the period. Fort L.P. acquired a new position in shares of Zoetis in the 2nd quarter valued at about $121,000. Finally, Private Capital Group LLC increased its holdings in shares of Zoetis by 118.4% in the 1st quarter. Private Capital Group LLC now owns 1,529 shares of the company's stock valued at $128,000 after purchasing an additional 829 shares during the period. Hedge funds and other institutional investors own 90.98% of the company's stock.
About Zoetis
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. Zoetis Zoeti